Pegylated recombinant human hyaluronidase - Halozyme

Drug Profile

Pegylated recombinant human hyaluronidase - Halozyme

Alternative Names: PEG PH20; PEG rHuPH-20; pegvorhyaluronidase alpha; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Halozyme Therapeutics
  • Developer Eisai Co Ltd; Genentech; Halozyme Therapeutics; Scripps Health; University of California at San Francisco
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Cholangiocarcinoma; Gallbladder cancer; Solid tumours
  • Preclinical Gastric cancer

Most Recent Events

  • 16 Oct 2017 Phase-I clinical trials in Cholangiocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy) in USA (IV) (NCT03267940)
  • 16 Oct 2017 Phase-I clinical trials in Gallbladder cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy) in USA (IV) (NCT03267940)
  • 06 Sep 2017 Halozyme Therapeutics plans a phase I trial for Cholangiocarcinoma and Gallbladder adenocarcinoma (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) (NCT03267940)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top